Abstract
This report aims to analyze the current and future potential of prostate
cancer pipeline by examining key fundamentals across the entire pipeline of
drug candidates. BioSeeker has identified three fundamental dimensions to
outline the competitive landscape within the pharmaceutical industry; compound
type, therapy area and target type.
This report is written for you to identify your competition and understand
which targeting strategies are at work within prostate cancer drug
development. It allows you to pin-point which competitors drugs' clinical
out-come may have bearing on your own drug development and who are developing
sequels to blockbuster drugs. This report also helps you to locate white-spots
in the competitive landscape, giving you little or no competition. Conversely
it may reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the
treatment of medical disorders. BioSeeker has surveyed the prostate cancer
field and identified 135 drug targets belonging to 193 drugs. This report,
Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis is
an open landscape of resources to build, fuel, and drive your scientific
competitive vehicle for the advancement of prostate cancer drugs.
In the report, BioSeeker reports on 116 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 193 prostate cancer drugs. The highest degree of distinctiveness among the
cancer drugs is achieved by sorting each of them according to drug target mix,
compound type and R&D approach. At the same time we are also identifying peer
groups of drugs, that is, drugs we consider suitable for head-to-head
comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into
the presence and relevance of protein-protein interactions between identified
targets of prostate drugs. No less than 300+ target-target interactions were
recognized among and between 110 of the 135 included prostate cancer drug
targets.
Why You Should Own Your Own Copy of this Report:
- 300+ pages, with more than 50 different tables and figures. Includes more
than 1,000 active links to drug target related resources on the Internet
- A 193 prostate cancer drugs analysis, under development by 135
investigators
- 135 unique, in-depth, drug target validating profiles, highlighting twelve
themes about the drug target, i.e. protein-protein interaction with other
prostate cancer drug targets, pursued cancer indications, drugs under
development, presence in the Cancer Genome Project etc.
- A unique drug target combination breakdown of prostate cancer drugs into
R&D approaches
- Unique drug-protein target interactome- and protein-protein interactome of
drug targets analysis
- Pathway profiling of prostate cancer drug targets
- Compound strategies based on sub-cellular localization of drug targets
- Expression levels of identified drug targets in prostate cancer tissue
- Structure based drug design in prostate cancer
- Pin-point which competitor drugs' clinical out-come may have bearing on
your own drug development
- Who are working on sequels to blockbuster drugs?
- Locate white-spots in the competitive landscape, giving you little or no
competition
In all, this report is a serious reference for any professional interested in
the development of oncology drug targets and the selection/validation of
targeting strategies.
View Cart
